News > Jellagen Boosts Scientific Advisory Board with New Appointments Dr Mike Barbeck and Dr Andy Weymann

Jellagen Boosts Scientific Advisory Board with New Appointments Dr Mike Barbeck and Dr Andy Weymann


Jellagen, a leader in advanced collagen biomaterials from marine sources, announces the appointments of Dr Mike Barbeck and Dr Andy Weymann to their Jellagen Scientific Advisory Board. Mike and Andy will join existing board members Professor Andrew Mearns Spragg, Dr Alex Pretsch, Dr Tim Morley and Dr Serban San-Marina.

Mike and Andy will add a wealth of biomaterial chemistry expertise, regulatory and commercial experience along with new product development support to Jellagen’s existing Scientific Advisory Board.

Dr Mike Barbeck has over 15 years’ experience in regenerative biomedical research working at Frankfurt and Mainz Universities. Mike has a thorough understanding of cellular and molecular biology acquired through many years of experimental science. He has expertise in the principles of biomaterial-mediated tissue regeneration within bone, and different collagen materials, resulting in 42 papers in peer reviewed journals with a h-index of 12. Mike is currently Managing Director for BerlinAnalytix GmbH, a company for preclinical in vitro and in vivo analyses as well as analyses of clinical biospiest hat tests a variety of commercially available and newly developed Medical Devices. Furthermore, he is Managing Director for ScientiFy GmbH, a technology and innovation consultancy that supports new innovative products from research and development to market launch.

Dr Andy Weymann brings extensive board, medical, regulatory, and business experience. Andy was Chief Medical Officer for Smith & Nephew (S&N), where he provided global leadership and oversight of Clinical, Scientific and Medical Affairs with accountability for patient and product safety. He was also a Board Member of S&N Switzerland and a Board Member of Actracsys, a company acquired by S&N. He currently holds Board Member and Advisory Board positions for several medical device and biotech companies. Prior to his corporate career, Andy was a physician in Switzerland practising in trauma and orthopaedic surgery after obtaining his Masters in Human Medicine at the University of Zurich, Switzerland. In addition to his medical degree, Andy holds a Master of Business Administration (MBA) from the Simon Business School at the University of Rochester, NY (USA).

Professor Andrew Mearns Spragg, Founder & CSO of Jellagen, comments:

I am delighted with Mike and Andy’s appointment to Jellagen’s SAB. I am looking forward to working with them together with our existing SAB members to help develop and refine Jellagen’s product development strategy and research goals. It’s an honour and a privilege to work with such a highly skilled and renowned Advisory Board.”

Find out more about the Jellagen Scientific Advisory Board here.